Day: November 17, 2021

Wholly-owned pipeline with three clinical-stage programs targeting significant inflammatory and immunology disease markets Dosing initiated in a multiple-ascending dose (MAD) Phase 1 trial for VTX958, an oral, selective tyrosine kinase type 2 (TYK2) inhibitor, and a Phase 1 trial for VTX2735, an oral Nod-like receptor protein 3 (NLRP3) inhibitor Completed upsized initial public offering (IPO) of common stock, raising approximately $174.3 million in gross proceeds, including full exercise of underwriters’ option to purchase additional shares ENCINITAS, Calif., Nov. 17, 2021 (GLOBE NEWSWIRE) — Ventyx Biosciences, Inc. (Nasdaq: VTYX), (“Ventyx” or the “Company”), a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders, today announced...

RIO DE JANEIRO, Brazil, Nov. 17, 2021 (GLOBE NEWSWIRE) — Vinci Partners Investments Ltd. (NASDAQ: VINP) (“Vinci Partners”, “we”, “us” or “our”), the controlling company of a leading alternative investment platform in Brazil, today reported third quarter 2021 earnings result. Vinci Partners issued a full earnings release and detailed presentation of its third quarter 2021 results, which can be accessed by clicking here. Webcast and Earnings Conference Call Vinci Partners will host a conference call at 5:00pm ET on Wednesday, November 17, 2021, to announce its third quarter 2021 results. To access the conference call via public webcast, please visit the Events & Presentations section of the Company’s website at https://ir.vincipartners.com/news-and-events/events-and-presentations. For those unable to listen to the live...

SINGAPORE, Nov. 17, 2021 (GLOBE NEWSWIRE) — Grindrod Shipping Holdings Ltd. (NASDAQ: GRIN) (JSE: GSH) (“Grindrod Shipping” or “Company” or “we” or “us” or “our”), a global provider of maritime transportation services predominantly in the drybulk sector, today announced its unaudited earnings results for the three months and nine months ended September 30, 2021. Financial Highlights for the three months Ended September 30, 2021Revenues of $135.1 million  Gross profit of $62.0 million  Profit for the period of $49.1 million  Profit for the period attributable to owners of the Company of $44.0 million, or $2.29 per ordinary share  Adjusted net income of $45.8 million, or $2.38 per ordinary share(1)Adjusted EBITDA of $69.0 million(1) Repurchased a combined total of 91,871 ordinary shares in the open market on NASDAQ and the JSE...